Non-alcoholic fatty liver disease

Paediatrics and Child Health (United Kingdom)

Volumn 23, Issue 12, 2013, Pages 529-534

  Della Corte, Claudia ^a   Liccardo, Daniela ^a   Mosca, Antonella ^b   Vania, Andrea ^b   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Children; Fatty liver; NAFLD; NASH

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOCOSAHEXAENOIC ACID; EXENDIN 4; FARNESOID X RECEPTOR; GLUCAGON LIKE PEPTIDE 1; INSULIN SENSITIZING AGENT; INTERLEUKIN 6; LEPTIN; LIRAGLUTIDE; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PLACEBO; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE COMPARISON; DRUG MECHANISM; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; INDUSTRIALIZATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCORING SYSTEM; SEDENTARY LIFESTYLE; WEIGHT REDUCTION;

EID: 84888430602     PISSN: 17517222     EISSN: 1878206X     Source Type: Journal    
DOI: 10.1016/j.paed.2013.08.003     Document Type: Review

References (13)

1. Alisi A., Ceccarelli S., Panera N., Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012, 2:132.
2. Alisi A., Locatelli M., Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010, 13:397-402.
3. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
4. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009, 49:809-820.
5. Day C.P. Non-alcoholic fatty liver disease: a massive problem. Clin Med 2011, 11:176-178.
6. Farrell G.C., van Rooyen D., Gan L., Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012 April, 6:149-171.
7. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., Benson J.T., Enders F.B., Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538-1544.
8. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
9. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
10. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. JClin Gastroenterol 2005, 39:540-543.
11. Nobili V., Bedogni G., Alisi A., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomized controlled clinical trial. Arch Dis Child 2011, 96:350-353.
12. Nobili V., Manco M., Devito R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128.
13. Schwimmer J.B., Pardee P.E., Lavine J.E., Blumkin A.K., Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008, 118:277-283.